research Scalp hair cortisol concentration in patients with alopecia areata and correlate its level with the disease variables
Higher stress levels may worsen alopecia areata, suggesting stress management is important for treatment.
Search
for
Sort by
Research
420-450 / 812 results 
research Efficacy and safety of tofacitinib in pediatric patients with alopecia areata: A prospective cohort study
Tofacitinib improved hair regrowth and quality of life in children with alopecia areata, with mild side effects.
research Baricitinib: Exploring the Safety Profile for the Treatment of Alopecia Areata
Baricitinib is effective for severe alopecia areata with manageable side effects, mainly upper respiratory infections.
research Regenerative Medicine-Based Treatment for Vitiligo: An Overview
Regenerative treatments for vitiligo show promise but need more research for long-term safety and effectiveness.
research Efficacy and safety of tofacitinib in patients with total and universal alopecia- A retrospective evaluation of 69 patients
Tofacitinib is effective for treating alopecia totalis and universalis, with some patients experiencing significant hair regrowth.
research Efficacy and Safety of Topical Tofacitinib for the Treatment of Alopecia Areata
Topical tofacitinib is effective and safe for treating alopecia areata.
research Improvement in health‐related quality of life and symptoms of anxiety and depression in patients with alopecia areata randomized to baricitinib or placebo: Results from two international randomized controlled trials
Patients with severe alopecia areata felt better and less anxious or depressed when treated with baricitinib compared to placebo.
research Distribution of SALT scores by Therapeutic Tesponse in Patients with Severe Alopecia After 52 weeks of Baricitinib Therapy
Baricitinib therapy helped many patients with severe alopecia regrow hair after 52 weeks.
research Case Report: Successful Treatment of Alopecia Universalis With Tofacitinib and Increased Cytokine Levels: Normal Therapeutic Reaction or Danger Signal?
Tofacitinib regrew hair in a man with total hair loss but raised cytokine levels, needing more research on possible side effects.
research Hair Growth Effect of Emulsion Extracted Brevilin A, a JAK3 Inhibitor, from Centipeda minima
CMX from Centipeda minima can significantly improve hair growth in mild to moderate balding.
research Patterns of clinical response in patients with alopecia areata treated with ritlecitinib in the ALLEGRO clinical development programme
Ritlecitinib shows promise for treating alopecia areata, especially with early and extended treatment.
research Biologics in the management of childhood atopic dermatitis
Biologics, especially Dupilumab, are effective and safe for treating severe childhood eczema.
research Safety of oral JAK inhibitors in treating alopecia areata: a systematic review and network meta-analysis
Oral JAK inhibitors are safe for alopecia areata, but baricitinib may cause more acne and infections.
research Drug-Induced Alopecia Areata From Upadacitinib
Upadacitinib may cause hair loss.
research The Diverse Experiences and Challenges of Individuals With Alopecia Areata: Survey Results From Finland
Alopecia areata greatly affects quality of life, with many experiencing mental health issues and lacking professional support.
research Editorial: Exploring innovative therapies for rare inflammatory skin diseases
New therapies for rare skin diseases show promise but need more research.
research Case Report: Successful treatment of pediatric alopecia universalis with ritlecitinib after failure of baricitinib
Ritlecitinib successfully treated a child's alopecia universalis after baricitinib failed.
research Ritlecitinib: Efficacy of a Novel Therapy for Severe Alopecia Areata in Patients Aged 12 Years and Older
Ritlecitinib is effective and safe for treating severe alopecia areata in people aged 12 and older.
research Etrasimod for alopecia areata: The scenario for a less extensive and moderate form
Etrasimod is safe but not effective for severe alopecia areata, though it may help milder cases.
research Discovery of a novel and highly selective JAK3 inhibitor as a potent hair growth promoter
MJ04, a new compound, effectively promotes hair growth and is a potential topical treatment for hair loss.
research The Good and Bad News About New Drugs for Treating Alopecia Areata
JAK inhibitors show promise for treating Alopecia Areata, while statins are not recommended.
research Treatment of alopecia areata with the janus kinase inhibitor upadacitinib: A retrospective cohort study
Upadacitinib improved hair regrowth and quality of life in alopecia areata patients with minimal side effects.
research Atopic diseases and the risk of alopecia areata among pre-teens and teenagers in Taiwan
Children with atopic diseases have a higher risk of developing alopecia areata.
research Emerging pharmacotherapies and regenerative solutions for promoting hair growth for androgenetic alopecia
New treatments for hair loss show promise but need more testing for effectiveness and safety.
research Precision therapeutics in non-scarring alopecia: a systemic genomic and pathway-based framework for targeted interventions
Personalized treatments for hair loss focus on specific genetic and biological pathways.
research Advances in dermatology research: A comprehensive literature review
Ongoing research and innovation are crucial for improving skin care and treatment.
research Psoriasis Course in Patients with Alopecia Areata Undergoing Baricitinib Therapy
Baricitinib improves alopecia areata and may help psoriasis but might not be ideal for psoriatic arthritis.
research COLLAB: A Global Survey of Clinical and Laboratory Assessment in Alopecia Areata by Hair Specialists
Hair specialists vary in testing for alopecia areata, highlighting the need for standard guidelines.
research Mesenchymal Stem Cell Therapy in Alopecia Areata: Visual and Molecular Evidence from a Mouse Model
Mesenchymal Stem Cell therapy shows promise for treating hair loss in Alopecia Areata.
research IL-17 axis is a significant driver of skin inflammation in Card14 mutant pityriasis rubra pilaris model mice
Blocking IL-17 can reduce skin inflammation in a mouse model of pityriasis rubra pilaris.